Mitsubishi Ufj Morgan Stanley Securities Co., Ltd. Vertex Pharmaceuticals Inc Transaction History

Mitsubishi Ufj Morgan Stanley Securities Co., Ltd.

$7.89 Million
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 23, 2023	SELL	$285.76 - $321.48 $31,433 - $35,362	-110 Reduced 52.38%	100 $29,000
Q1 2022 May 04, 2022	BUY	$221.42 - $260.97 $2,214 - $2,609	10 Added 5.0%	210 $55,000
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $35,402 - $44,690	200 New	200 $44,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Morgan Stanley Securities Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Morgan Stanley Securities Co., Ltd. with notifications on news.

Account